NAD+ and CD38 — why supplementing alone might not be enough

The molecule responsible for much of this consumption is called CD38, and it barely appears in popular writing about NAD+. This is a significant omission. Understanding CD38 doesn't make the NAD+ story less compelling; it makes it more precise and, for people designing serious protocols, considerably more actionable.

CD38 is an ectoenzyme — a protein that sits on the surface of cells with its catalytic domain facing outside — and its primary enzymatic activity is the hydrolysis of NAD+ and its precursors. It breaks them down. CD38 cleaves NAD+ into nicotinamide and ADP-ribose with high efficiency. It can also hydrolyze NAAD and NMN, which means it acts not just on NAD+ itself but on parts of the pathway that generate it. Evolutionarily, CD38 is primarily an immune and inflammatory signaling molecule; it's highly expressed on immune cells and in lymphoid tissue, and it plays a role in calcium signaling and inflammatory activation. But its NAD+-consuming activity is a side effect of that biology that has real consequences for cellular NAD+ homeostasis.

Here's the key fact: CD38 expression and activity rise substantially with age. Eduardo Chini's lab at the Mayo Clinic has produced some of the most rigorous work characterizing this relationship. Their research in mouse models showed that CD38 activity increases approximately two- to threefold between young adulthood and old age, and that this increase is sufficient to account for a substantial portion of the NAD+ decline observed in aged tissues — the same decline that the longevity-NAD+ hypothesis identifies as central to aging-associated dysfunction. When Chini's group knocked out CD38 in aged mice, NAD+ levels were preserved at near-youthful levels. When they inhibited CD38 pharmacologically, NAD+ rose even in animals where precursor supplementation alone had limited effect.

What this means practically is that the NAD+ deficit in aging tissues is not simply a production problem. It's partly a degradation problem. The cell's capacity to synthesize NAD+ through the salvage pathway — the route that NMN and NR use — is not dramatically impaired with age. What is impaired is the ability to maintain NAD+ against a rising tide of enzymatic consumption. If CD38 activity doubles, you have to double your precursor input just to hold NAD+ steady, let alone raise it. The supplementation strategies that showed dramatic effects in young or CD38-normal animals look less impressive in aged animals not because the precursors stop working but because CD38 is eating the product faster than the salvage pathway can replace it.

This is not a hypothetical edge case. It's part of why some researchers believe precursor supplementation alone — while genuinely useful — may not be sufficient to produce the NAD+ elevations in aged tissue that drove the mouse longevity results. The dose required to meaningfully raise intracellular NAD+ in an aged person with elevated CD38 activity may be substantially higher than the dose that worked in a younger animal with normal CD38 activity, which may explain some of the dose-response observations in human trials.

CD38 inhibition as a complementary strategy has consequently become an active area of research. The logic is straightforward: if you block CD38's ability to consume NAD+, the same precursor supplementation produces higher intracellular NAD+ than it otherwise would. You're working with the production side and addressing the consumption side simultaneously. In the Chini lab's work, the combination of precursor supplementation with CD38 inhibition produced NAD+ elevations substantially greater than either alone.

The practical challenge is that potent, selective CD38 inhibitors are primarily a pharmaceutical research area, not a supplement category. Drugs like daratumumab — an anti-CD38 monoclonal antibody used in multiple myeloma — are clinical-grade interventions with significant immunological effects that are not appropriate for healthy people interested in longevity. The search for accessible, lower-potency CD38 inhibitors has moved toward natural flavonoids, which led to a considerable amount of interest in apigenin.

Apigenin is a flavonoid found in parsley, chamomile, celery, and other common plant foods. In cell culture and animal studies, it inhibits CD38 activity. Anthony Sauve at Cornell and Chini's group at Mayo both referenced apigenin in the context of CD38 inhibition, and the popular longevity community — including Sinclair's public communications — took this up enthusiastically. Apigenin supplements became part of standard longevity stacks alongside NMN and resveratrol. The science behind apigenin's CD38 inhibitory activity in isolated cell systems is real. The translation to meaningful CD38 inhibition at doses achievable through supplementation in humans is far less established. Flavonoids have poor oral bioavailability as a class; what reaches systemic circulation after ingestion is a small fraction of what was in the capsule, and the relationship between circulating apigenin levels and tissue CD38 inhibition in humans has not been rigorously characterized.

Quercetin follows a similar logic. It's a more abundant dietary flavonoid, also with demonstrated CD38 inhibitory activity in vitro, also with bioavailability limitations in oral form. The combination of quercetin with other agents — like dasatinib in senolytic research, or with various absorption enhancers — has been studied for different purposes, and some quercetin formulations use liposomal delivery or co-administration with bromelain to improve absorption. Whether these approaches produce meaningful CD38 inhibition in aged human tissue at practical doses remains an active research question with no definitive answer yet.

The scientific community is working on more potent and specific CD38 inhibitors that might be suitable for clinical use. Flavonoids are the low-risk, accessible end of this spectrum — they're dietary compounds with established safety profiles, the worst plausibly achievable outcome from taking them is minimal CD38 inhibition. On the other end of the spectrum, the pharmaceutical development of selective CD38 inhibitors for aging applications — without the broad immunosuppressive effects of the oncology drugs — is ongoing in several research programs. This is where the field is moving, but it hasn't arrived yet in a form that belongs in a practical protocol.

There's a second major consumer of NAD+ that deserves mention alongside CD38: the PARP family of enzymes. PARP — poly-ADP-ribose polymerase — uses NAD+ as a substrate to perform DNA repair. When cells experience DNA damage, PARP activity rises sharply, consuming NAD+ in large quantities to execute the repair process. In normally aging cells, chronic low-grade DNA damage accumulates and PARP activity rises correspondingly, creating an additional NAD+ consumption demand on top of CD38. Charles Brenner at City of Hope has written about the PARP-CD38 competition as one of the key dynamics driving age-related NAD+ decline: you have two major consumers — PARP for DNA repair signaling and CD38 for immune-related NAD+ catabolism — both rising with age, competing with the salvage pathway for a diminishing supply.

The implication for protocol design is significant. The NAD+ longevity story, in its simplest form, is: levels decline with age, sirtuins need NAD+, supplement to restore levels. That's true as far as it goes. What it leaves out is the dynamic equilibrium between production and consumption, the age-related shift in that equilibrium driven by CD38 and PARP, and the consequence that supplementation strategies designed for younger animals or people with normal CD38 activity may require recalibration when CD38 activity is elevated. A 250 mg per day NMN protocol that works beautifully in a 35-year-old may be insufficient in a 65-year-old with age-associated CD38 elevation — not because NMN stops working, but because the consumption side of the equation has changed.

This doesn't mean supplementation is futile — the data shows blood NAD+ rises in aged subjects with precursor supplementation, and that matters. It means the more complete protocol likely involves addressing both sides: precursor supply and degradation management. Whether that degradation management is achievable through dietary flavonoids at current supplement doses is unclear. Whether it requires pharmaceutical-grade CD38 inhibitors is the subject of ongoing research. What's clear is that thinking about NAD+ only as a production problem misses half of the biology — and for people in the age range where NAD+ decline has its most consequential effects, the consumption half may be the more important one to understand.

The deeper implication reaches into how we should think about the whole NAD+ supplementation category. It's not that supplementing is wrong or pointless — there's reasonable evidence it does something useful. It's that the distance between "I raised my blood NAD+" and "I addressed the cellular NAD+ dynamics that matter for aging" may be larger than the simple version of the story suggests, and closing that gap probably requires engaging with the biology at more than one point.